Moderna's mRNA Vaccine Clears Safety Hurdle as William Blair Boosts Outlook

Moderna's mRNA vaccine has shown no new safety signals after patients received up to nine doses of Keytruda in combination with the personalized vaccine. According to a recent update, ongoing follow-up will evaluate overall survival.

The news comes as William Blair upgraded Moderna from Market Perform to Outperform, citing potential growth opportunities for the company. The investment firm's upgrade is likely to boost investor confidence and propel the stock higher.

Moderna has also maintained its long-term collaboration with Merck, a partnership that was exercised in 2022. Under this agreement, Moderna handles manufacturing and process development, while Merck runs clinical trials. This partnership will continue to drive innovation in the field of mRNA-based therapies.